Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Fundamental Analysis of Alembic Pharmaceuticals Ltd

About the Company - Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 5035.41 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsAlembic Road, Vadodra Gujarat 390003apl.investors@alembic.co.in
http://www.alembicpharmaceuticals.com
Management
NamePosition Held
Mr. Chirayu AminChairman & CEO
Mr. Pranav AminManaging Director
Mr. Shaunak AminManaging Director
Mr. R K BahetiDirector - Finance & CFO
Mr. K G RamanathanIndependent Director
Mr. Pranav ParikhIndependent Director
Mr. Paresh SaraiyaIndependent Director
Dr. Archana HingoraniIndependent Director
Mr. Ashok BaratIndependent Director
Mr. Jai DiwanjiIndependent Director

Alembic Pharmaceuticals Ltd. Share Price Update

Share PriceValue
Today₹725.50
Previous Day₹720.60

Basic Stock Data of Alembic Pharmaceuticals Ltd

Market Cap 14,172 Cr.
Current Price 721
High / Low839/462
Stock P/E26.6
Book Value 227
Dividend Yield1.10 %
ROCE7.40 %
ROE7.20 %
Face Value 2.00

Alembic Pharmaceuticals Ltd Quarterly Results

Month

Alembic Pharmaceuticals Ltd Quarterly Chart

Alembic Pharmaceuticals Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales1,4651,5201,8632,0563,1663,1053,1313,9354,6065,3935,3065,6535,997
Expenses1,2461,2681,5061,6532,1592,4902,4883,0613,3833,9134,4324,9705,151
Operating Profit2192523584031,0076156438741,2231,480874682845
OPM %15%17%19%20%32%20%21%22%27%27%16%12%14%
Other Income134447279-398756-223
Interest3815104553182716185059
Depreciation343540447283105115157183287275274
Profit before tax1612063113599365295417491,0001,368625355535
Tax %19%20%24%21%23%23%22%21%20%19%17%4%
Net Profit1301652362837204034135838011,146521342532
EPS in Rs6.908.7712.4915.0138.2021.3921.8931.0043.9758.3326.5017.4027.05
Dividend Payout %20%29%24%23%9%19%18%18%23%24%38%46%

Alembic Pharmaceuticals Ltd Profit & Loss Yearly Chart

Alembic Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years::14%
5 Years::13%
3 Years::7%
TTM::11%

Alembic Pharmaceuticals Ltd Growth

Compounded Profit Growth
10 Years::8%
5 Years::-3%
3 Years::-25%
TTM::104%

Alembic Pharmaceuticals Ltd Growth

Stock Price CAGR
10 Years::13%
5 Years::5%
3 Years::-10%
1 Year::20%

Alembic Pharmaceuticals Ltd Growth

Return on Equity
10 Years::21%
5 Years::18%
3 Years::14%
Last Year::7%

Alembic Pharmaceuticals Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital38383838383838383839393939
Reserves3574656388471,5601,8652,1822,6813,1825,0285,1984,3314,431
Borrowings353187109264114897081,1281,747584717722869
Other Liabilities3043584324937186981,0139311,0221,0581,1671,0901,116
Total Liabilities1,0521,0481,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,455
Fixed Assets2683443975477087999931,1581,5521,7881,7982,3982,603
CWIP58322183933961,0101,5511,8462,1832,304601478
Investments333287504249182361189698
Other Assets7236687961,0091,5411,4441,8962,0192,5732,5022,9023,0873,277
Total Assets1,0521,0481,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,455

Alembic Pharmaceuticals Ltd Reserves and Borrowings Chart

Alembic Pharmaceuticals Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 1422652401729483293128124491,463552724
Cash from Investing Activity -56-67-81-256-307-486-884-756-731-840-372-448
Cash from Financing Activity -45-229-15187-224-12950359155-597-217-262
Net Cash Flow41-3183417-286-69115-12726-3714

Alembic Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days505654644040614569245668
Inventory Days133143159196266269302356417431406315
Days Payable108129148166264213313237220194178145
Cash Conversion Cycle75706594429651164266261283237
Working Capital Days615950714972936411894118119
ROCE %29%31%44%38%66%29%22%23%24%26%11%7%

Alembic Pharmaceuticals Ltd Financial Efficiency Indicators Chart

No valid data available for the Shareholding

Alembic Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Alembic Pharmaceuticals Ltd Shareholders

Alembic Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
DSP Mid Cap Fund47660712.46370.18
Kotak Small Cap Fund - Regular Plan38651252.44300.2
DSP Tax Saver Fund17271231.13134.15
DSP Healthcare Fund12330685.8295.77
DSP Top 100 Equity Fund5440881.4242.26
Aditya Birla Sun Life Small Cap Fund4507520.7835.01
DSP Small Cap Fund4381280.2834.03
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund2965050.7323.03
Aditya Birla Sun Life Pharma & Healthcare Fund1611382.412.52
UTI Healthcare Fund1200001.29.32

Alembic Pharmaceuticals Ltd ROCE Trend

Alembic Pharmaceuticals Ltd EPS Trend

Alembic Pharmaceuticals Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)17.4026.5060.8143.9731.00
Diluted EPS (Rs.)17.4026.5060.8143.9731.00
Cash EPS (Rs.)32.9940.8366.0550.8237.55
Book Value[Excl.RevalReserv]/Share (Rs.)222.36266.47257.80169.25144.19
Book Value[Incl.RevalReserv]/Share (Rs.)222.36266.47257.80169.25144.19
Revenue From Operations / Share (Rs.)287.59269.95274.39244.34208.74
PBDIT / Share (Rs.)36.1847.0479.7565.1446.84
PBIT / Share (Rs.)22.1732.4570.4256.8040.73
PBT / Share (Rs.)19.6131.5569.6053.0439.75
Net Profit / Share (Rs.)18.9726.2356.7242.4731.44
NP After MI And SOA / Share (Rs.)17.4026.5059.9443.9731.00
PBDIT Margin (%)12.5817.4229.0626.6622.44
PBIT Margin (%)7.7012.0225.6623.2419.51
PBT Margin (%)6.8211.6825.3621.7019.04
Net Profit Margin (%)6.599.7120.6717.3815.06
NP After MI And SOA Margin (%)6.059.8121.8417.9914.85
Return on Networth / Equity (%)7.829.9422.9725.7421.49
Return on Capital Employeed (%)9.5811.7925.4925.2623.34
Return On Assets (%)5.537.3117.5613.8312.23
Long Term Debt / Equity (X)0.000.000.030.270.18
Total Debt / Equity (X)0.140.120.030.540.34
Asset Turnover Ratio (%)0.770.730.790.770.86
Current Ratio (X)1.781.672.011.411.31
Quick Ratio (X)0.870.720.850.720.66
Inventory Turnover Ratio (X)0.860.780.930.951.05
Dividend Payout Ratio (NP) (%)57.4752.820.0039.3215.55
Dividend Payout Ratio (CP) (%)31.8334.060.0033.0512.99
Earning Retention Ratio (%)42.5347.180.0060.6884.45
Cash Earning Retention Ratio (%)68.1765.940.0066.9587.01
Interest Coverage Ratio (%)14.1752.1597.8545.2147.96
Interest Coverage Ratio (Post Tax) (%)8.4330.0870.5932.0933.19
Enterprise Value (Cr.)10301.5015131.7919003.4511697.0810722.89
EV / Net Operating Revenue (X)1.822.853.522.542.73
EV / EBITDA (X)14.4916.3712.129.5312.14
MarketCap / Net Operating Revenue (X)1.722.753.522.182.54
Retention Ratios (%)42.5247.170.0060.6784.44
Price / BV (X)2.232.783.703.123.68
Price / Net Operating Revenue (X)1.722.753.522.182.54
EarningsYield0.030.030.060.080.05

Alembic Pharmaceuticals Ltd Profitability Ratios (%)

Alembic Pharmaceuticals Ltd Liquidity Ratios

Alembic Pharmaceuticals Ltd Liquidity Ratios (%)

Alembic Pharmaceuticals Ltd Interest Coverage Ratios (%)

Alembic Pharmaceuticals Ltd Valuation Ratios

Strength and Weakness of Alembic Pharmaceuticals Ltd Stock

StrengthWeakness

The company has shown consistent growth in sales and profit over the years.

The stock has a low average ROCE, which may not be favorable.

The stock has a high average Working Capital Days, which may not be favorable.

The stock has a high average Cash Conversion Cycle, which may not be favorable.

The company has higher borrowings compared to reserves, which may suggest financial risk.

Related Posts